Britain and America have agreed to a important bilateral deal that will maintain zero levies on UK pharmaceutical products being sold in the American market.
Agreement Details of the Accord
As part of the deal, the UK has committed to raise spending on pharmaceuticals through the National Health Service (NHS). This move guarantees that import taxes on these crucial exports will remain at nothing for a timeframe of the next three years.
This agreement is in response to recent statements to hike tariffs on patented pharmaceutical imports, with increases mentioned up to 100%.
"This arrangement with the Britain reinforces the international landscape for cutting-edge drugs and establishes much-needed fairness to U.S.–U.K. medicine commerce," an announcement said.
Commercial Significance
Medicines are one of the the United Kingdom's biggest exports to the America, which is easily the biggest destination for large UK drugmakers.
Statistics indicate that in the year to the end of the third quarter, the UK sold pharmaceutical products totaling £11.1bn to the US. This value made up a significant portion of British export trade in that timeframe.
"This agreement safeguards employment, increases capital expenditure and facilitates the UK to emerge as a global hub for medical research," a government official stated.
Specific UK Commitments
The agreement entails several notable commitments from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a target to increase overall health service expenditure on drugs from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must return to the NHS to stay within budget will be restricted at fifteen percent. Previously, refunds were more than twenty percent.
Broader Context
The pact follows a long-running dispute between the drug companies and the British authorities over medicine costs and approval rates.
This friction were exacerbated by claims that US consumers were charged a premium for the identical medicines than consumers in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been paused or abandoned, while major expansions have been directed toward US facilities.
The Science Minister publicly accepted that the NHS must increase expenditure on drugs, noting that its spending on drugs had shrunk as a proportion of its overall budget over the last ten years.
